Events | 2020.03.02
ADx Healthcare and Shinyukai Group Collaborate with Ixlayer to launch Polygenic-risk score Alzheimer’s test in Japan
On the 3rd of March, Ixlayer in collaboration with ADx Healthcare, a provider of Alzheimer's disease-related testing and Nakanoshima Clinic part of Shinyukai group based in Osaka, Japan, announcing the launch of Polygenic-risk score for early detection of Alzhiemers diesease in Japan. This announcement coincides with the state of NY announcing a five-year initiative to collect and disseminate genomic data on 1 million people with Alzheimer's disease. In Japan more 4.6 million people are living with dementia. And this number is expected to rise significantly as the population ages. Worldwide, at least 44 million people are living with dementia, making the disease a global health crisis that must be addressed. The GenoRisk targeted panel offering will look at 32 genes that have been identified as highly penetrant genetic conditions. The first Clinic to offer GenoRisk Alzheimer's test is Nakanoshima health center. Nakanoshima is one of five clinics/health centers owned by the Shinyukai group, whose headquarters are in Kyoto, Japan. Nakanoshima Clinic's focus is on early detection and prevention of diseases.
(PRWeb March 02, 2020)
Read the full story at https://www.prweb.com/releases/adx_healthcare_and_shinyukai_group_collaborate_with_ixlayer_to_launch_polygenic_risk_score_alzheimers_test_in_japan/prweb16949022.htm
For more information, please visit
https://www.prweb.com/releases/adx_healt[...]est_in_japan/prweb16949022.htm
